ERBB2 and neoplasm: Overall, the enhanced chemotherapeutic efficacy of the HER2-LsbMDDs can be attributed to the preferable biodistribution to tumor sites by active targeting of the HER2-LsbMDDs endowed with non-covalently bound of BsAbs and the enhanced DTX uptake amount via an endocytosis-mediated pathway leading to a greater accumulation and a longer retention of the DTX in the tumor.